Proton therapy for pancreatic cancer: real-world single-center experience of efficacy, toxicity, and predictors of outcome
Proton therapy for pancreatic cancer was well tolerated, though outcomes remained modest compared to recent studies utilizing higher doses and optimized protocols. Low toxicity supports proton therapy's theoretical advantages. Dose escalation and protocol optimization may enhance outcomes. Prospective studies with larger cohorts are warranted.
Authors
- Fabian Eberle (ORCID: https://orcid.org/0000-0002-1473-6065)
- Hilke Vorwerk (ORCID: https://orcid.org/0000-0001-7542-683X)
- Daniel Habermehl (ORCID: https://orcid.org/0009-0007-7316-6422)
- Ahmed Gawish (ORCID: https://orcid.org/0000-0001-5557-7438)
- Linda Agolli (ORCID: https://orcid.org/0000-0003-1534-4386)
- Thomas Held (ORCID: https://orcid.org/0000-0002-3913-4693)
- Sebastian Adeberg (ORCID: https://orcid.org/0000-0001-8463-514X)
- Houmam Anees (ORCID: https://orcid.org/0009-0002-2427-0841)
- Kerem Tuna Tas
- Philipp Lishewski
- Klemens Zink
- Anja Rinke
- Zelal Geyik
Institutions
- Goethe University Frankfurt (DE)
- Philipps University of Marburg (DE)
- Breast Cancer Research Foundation (US)
- Justus-Liebig-Universität Gießen (DE)
- Heidelberg University (DE)
- Universitätsklinikum Gießen und Marburg (DE)
- University Hospital Heidelberg (DE)
- National Center for Tumor Diseases (DE)
- Institute of Environmental Protection (PL)
- Institute for Advanced Medical Research (US)
- University Hospital Frankfurt (DE)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2026-02-26
- DOI
- https://doi.org/10.3389/fonc.2026.1710943
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00